FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938757954> ?p ?o ?g. }

• W2938757954 endingPage "ii57" @default.
• W2938757954 startingPage "ii56" @default.
• W2938757954 abstract "Background: The global, randomized, double-blind, phase 3 KEYNOTE-189 study (NCT02578680) showed significantly improved OS and PFS with pembrolizumab (pembro) + pemetrexed (pem) + platinum compared with placebo + pem + platinum with a manageable safety profile in pts with previously untreated metastatic nonsquamous NSCLC without targetable EGFR/ALK aberrations|. We present safety and tolerability data from Japanese pts enrolled in KEYNOTE-189. Methods: Eligible pts enrolled in Japan during the global or extension study of KEYNOTE-189 were randomized 2:1 to pembro 200 mg Q3W or placebo for up to 35 cycles (2 y); all pts received pem 500 mg/m2 (until progressive disease or intolerable toxicity) and 4 cycles of carboplatin AUC 5 or cisplatin AUC 75 mg/m2. Safety and tolerability were assessed by clinical review of all relevant parameters; adverse events (AEs) and laboratory abnormalities were graded per NCI CTCAE v4.0. Results: Of 40 pts enrolled in Japan (global study, n = 10; extension study, n = 30), 25 were randomized to the pembro arm, and 15 to the placebo arm. There were no meaningful differences in baseline characteristics, apart from a smaller proportion of pts with brain metastases (16% vs 33%), and larger proportion with PD-L1 TPS <1% (56% vs 40%) and cisplatin recipients (72% vs 53%) in the pembro vs placebo arm, respectively. The median (range) follow-up was 5.6 (2.4–12.9) mo and 7.0 (2.4–19.8) mo in the pembro and placebo arms, respectively. There were no deaths due to AEs. Grade 3/4 AEs occurred in 13 pts (52%) in the pembro arm and 8 (53%) in the placebo arm. 6 (24%) vs 3 pts (20%) had immune-mediated AEs and infusion reactions, with no events of pneumonitis reported in the pembro arm vs 2 (13.3%) in the placebo arm. Overall, AEs led to treatment discontinuation in 4 (16%) pts in the pembro vs 3 (20%) pts in the placebo arm. Conclusions: Pembro + pem + platinum demonstrated a tolerable and manageable safety profile in Japanese pts, generally consistent with the overall pt population in the global KEYNOTE-189 study. No new safety concerns were identified in Japanese pts. Clinical trial identification: NCT02578680. Editorial acknowledgement: Medical writing assistance was provided by Shilpa Aggarwal, PhD, of C4 MedSolutions, LLC (Yardley, PA, USA), a CHC Group company and was funded by funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Legal entity responsible for the study: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Disclosure: H. Horinouchi: Corporate-sponsored research: MSD, Eli Lilly, BMS. N. Nogami: Honoraria: Pfizer Inc., Chugai Pharmaceutical Co. Ltd, Eli Lilly, Taiho Pharmaceutical Co. Ltd., AstraZeneca, Kyowa Hakko Kirin, Ono Pharmaceutical Co. Ltd., MSD. H. Saka: Grants/research support: AstraZeneca, MSD, Ono Pharmaceutical; Honoraria: AstraZeneca, MSD, Ono Pharmaceutical, Chugai Pharmaceutical, Boehringer Ingelheim, Kyorin Pharmaceutical. M. Nishio: Grants and personal fees: Ono Pharmaceutical, Bristol-Myers Squibb, Pfizer, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, Boehringer-Ingelheim, MSD, Novartis; Personal fees: Daiichi Sankyo Healthcare, Merck Serono; Grants: Astellas, outside the submitted work. T. Tokito: Honoraria: AstraZeneca, MSD, Ono, Chugai. T. Takahashi: Grants, personal fees: Ono Pharmaceutical Co., Ltd., MSD K.K., AstraZeneca KK, Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K.; Grants: Pfizer Japan Inc.; Personal fees: Boehringer Ingelheim Japan, Inc, Roche Diagnostics K.K. K. Kasahara: Grants, honoraria: Boehringer Ingelheim; Honoraria: Pfizer, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceuticals, AstraZeneca, MSD. Y. Hattori: Research funding: MSD, Ono; Honoraria: AstraZeneca, Boehringer Ingelheim, Chugai, Eli Lilly, MSD, Novartis, Ono, Taiho. E. Ichihara: Research grants: Eli Lilly, MSD. N. Adachi, T. Sawada, T. Shimamoto, K. Noguchi: Employee: MSD K.K., Tokyo, Japan. M.C. Pietanza: Employee: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. T. Kurata: Research grants: AstraZeneca, MSD; Honoraria: AstraZeneca, MSD, Ono, Bristol-Myers Squibb, Chugai, Eli Lilly." @default.
• W2938757954 created "2019-04-25" @default.
• W2938757954 creator A5000600621 @default.
• W2938757954 creator A5015604127 @default.
• W2938757954 creator A5018690593 @default.
• W2938757954 creator A5040778303 @default.
• W2938757954 creator A5042110139 @default.
• W2938757954 creator A5045508144 @default.
• W2938757954 creator A5050389295 @default.
• W2938757954 creator A5054682168 @default.
• W2938757954 creator A5063817865 @default.
• W2938757954 creator A5068743826 @default.
• W2938757954 creator A5068793485 @default.
• W2938757954 creator A5069589468 @default.
• W2938757954 creator A5075659023 @default.
• W2938757954 creator A5078287634 @default.
• W2938757954 creator A5083502759 @default.
• W2938757954 date "2019-04-01" @default.
• W2938757954 modified "2023-09-27" @default.
• W2938757954 title "Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study" @default.
• W2938757954 doi "https://doi.org/10.1093/annonc/mdz063.049" @default.
• W2938757954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32131289" @default.
• W2938757954 hasPublicationYear "2019" @default.
• W2938757954 type Work @default.
• W2938757954 sameAs 2938757954 @default.
• W2938757954 citedByCount "0" @default.
• W2938757954 crossrefType "journal-article" @default.
• W2938757954 hasAuthorship W2938757954A5000600621 @default.
• W2938757954 hasAuthorship W2938757954A5015604127 @default.
• W2938757954 hasAuthorship W2938757954A5018690593 @default.
• W2938757954 hasAuthorship W2938757954A5040778303 @default.
• W2938757954 hasAuthorship W2938757954A5042110139 @default.
• W2938757954 hasAuthorship W2938757954A5045508144 @default.
• W2938757954 hasAuthorship W2938757954A5050389295 @default.
• W2938757954 hasAuthorship W2938757954A5054682168 @default.
• W2938757954 hasAuthorship W2938757954A5063817865 @default.
• W2938757954 hasAuthorship W2938757954A5068743826 @default.
• W2938757954 hasAuthorship W2938757954A5068793485 @default.
• W2938757954 hasAuthorship W2938757954A5069589468 @default.
• W2938757954 hasAuthorship W2938757954A5075659023 @default.
• W2938757954 hasAuthorship W2938757954A5078287634 @default.
• W2938757954 hasAuthorship W2938757954A5083502759 @default.
• W2938757954 hasBestOaLocation W29387579541 @default.
• W2938757954 hasConcept C121608353 @default.
• W2938757954 hasConcept C126322002 @default.
• W2938757954 hasConcept C141071460 @default.
• W2938757954 hasConcept C142724271 @default.
• W2938757954 hasConcept C143998085 @default.
• W2938757954 hasConcept C197934379 @default.
• W2938757954 hasConcept C204787440 @default.
• W2938757954 hasConcept C27081682 @default.
• W2938757954 hasConcept C2776256026 @default.
• W2938757954 hasConcept C2776694085 @default.
• W2938757954 hasConcept C2777240266 @default.
• W2938757954 hasConcept C2777701055 @default.
• W2938757954 hasConcept C2778239845 @default.
• W2938757954 hasConcept C2778375690 @default.
• W2938757954 hasConcept C2780057760 @default.
• W2938757954 hasConcept C2780580376 @default.
• W2938757954 hasConcept C2781451048 @default.
• W2938757954 hasConcept C71924100 @default.
• W2938757954 hasConceptScore W2938757954C121608353 @default.
• W2938757954 hasConceptScore W2938757954C126322002 @default.
• W2938757954 hasConceptScore W2938757954C141071460 @default.
• W2938757954 hasConceptScore W2938757954C142724271 @default.
• W2938757954 hasConceptScore W2938757954C143998085 @default.
• W2938757954 hasConceptScore W2938757954C197934379 @default.
• W2938757954 hasConceptScore W2938757954C204787440 @default.
• W2938757954 hasConceptScore W2938757954C27081682 @default.
• W2938757954 hasConceptScore W2938757954C2776256026 @default.
• W2938757954 hasConceptScore W2938757954C2776694085 @default.
• W2938757954 hasConceptScore W2938757954C2777240266 @default.
• W2938757954 hasConceptScore W2938757954C2777701055 @default.
• W2938757954 hasConceptScore W2938757954C2778239845 @default.
• W2938757954 hasConceptScore W2938757954C2778375690 @default.
• W2938757954 hasConceptScore W2938757954C2780057760 @default.
• W2938757954 hasConceptScore W2938757954C2780580376 @default.
• W2938757954 hasConceptScore W2938757954C2781451048 @default.
• W2938757954 hasConceptScore W2938757954C71924100 @default.
• W2938757954 hasLocation W29387579541 @default.
• W2938757954 hasOpenAccess W2938757954 @default.
• W2938757954 hasPrimaryLocation W29387579541 @default.
• W2938757954 hasRelatedWork W2049286103 @default.
• W2938757954 hasRelatedWork W2303758877 @default.
• W2938757954 hasRelatedWork W2378767654 @default.
• W2938757954 hasRelatedWork W2566596022 @default.
• W2938757954 hasRelatedWork W2770587120 @default.
• W2938757954 hasRelatedWork W2883512185 @default.
• W2938757954 hasRelatedWork W2922729092 @default.
• W2938757954 hasRelatedWork W2948776902 @default.
• W2938757954 hasRelatedWork W2981688104 @default.
• W2938757954 hasRelatedWork W3206685234 @default.
• W2938757954 hasVolume "30" @default.
• W2938757954 isParatext "false" @default.
• W2938757954 isRetracted "false" @default.
• W2938757954 magId "2938757954" @default.
• W2938757954 workType "article" @default.